are ATX-304 and SANA proven human weight-loss drugs?

updated

both compounds crossed into human experiments. neither has crossed into an approved, durable weight-loss evidence package.

verdict: early human signal, proven-drug claim unsupported (short trials / long-term outcomes absent)

quick answer

ATX-304 has a 28-day randomized diabetes study and a small eight-week obesity conference report. SANA has a short phase 1A/B program with exploratory weight and metabolic endpoints. Neither establishes durable weight-loss efficacy, long-term safety, or approved use.

the evidence

these are not animal-only programs. (supported)

ATX-304 reduced fasting glucose and blood pressure in a short randomized diabetes study. SANA reported early weight and glucose findings in phase 1 participants.

the human clocks are short. (gap)

A 28-day paper, an eight-week conference report, and a 15-day multiple-dose phase 1 cohort cannot establish durable obesity efficacy or chronic interaction and reproductive safety.

early safety signals remain visible. (risk)

Two of three participants at SANA's highest single exposure developed reversible renal tubular injury. ATX-304 lacks a published human terminal half-life, and its displayed 11-hour value is mouse-only and graph-derived.

bottom line

phase 1 or pilot movement is evidence, not confirmation.

scores

  • human exposure: 58 · both compounds reached controlled studies
  • durable weight loss: 12 · no mature long-term outcome program
  • safety depth: 16 · short exposure and a high-dose renal signal
  • approval: 0 · neither is approved

sources

  1. Steneberg P et al. JCI Insight. 2018. PMID 29925691. Primary O304 mechanism, animal, and randomized TELLUS clinical paper.
  2. Steneberg P et al. JCI Insight supplemental material. 2018. Primary supplemental figures and nonclinical study details for O304.
  3. ATX-304 obesity and prediabetes pilot. Diabetes. 2026. Abstract 1782-P. Small randomized conference report of ATX-304 in 23 adults with obesity and prediabetes.
  4. Cal L et al. 2025. PMID 40527924. Primary SANA or MVD1 chemistry, creatine-thermogenesis, animal-efficacy, phase 1 PK, and safety paper.

keep reading

claim checks

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.